Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efsubaglutide Alfa in Type 2 Diabetes
NCT06849843Phase 2Completed
- Sponsor
- Shanghai Innogen Pharmaceutical Technology Co., Ltd.
- Start
- Dec 2024
- Primary completion
- May 2025
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised trial of efsubaglutide alfa in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd. Primary endpoint: Glycated Hemoglobin at 12 weeks. Started Dec 2024; status: completed.
02
Drugs
efsubaglutide alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06849843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06849843.